Evaluation of clinical prognosis of stage II and III melanoma patients treated with hyperthermic isolated limb perfusion (HILP)

Satoko Shibata, Yoshiyuki Murakami, Yoichi Moroi, Shonosuke Nagae, Kazunori Urabe, Tetsuya Koga, Masutaka Furue, Juichiro Nakayama

Research output: Contribution to journalArticlepeer-review

Abstract

We performed hyperthermic isolated limb perfusion (HILP) in 21 patients (total: 25 procedures) with malignant melanoma including 13 cases of stage III and 8 cases of stage II from 1993 to 1998. All patients received radical resection of their tumors, lymph node dissection and immunochemotherapy. Local recurrences and/or distant metastases developed in 7 of the 21 cases after HILP treatment. The median disease-free time in these cases was 6 months. All recurrent cases already had metastases in regional lymph node(s) (stage III) and 6 had in-transit metastases when HILP was performed. NK activities of the recurrent patients were relatively lower than those of non-recurrent patients during and after HILP, although no difference in T cell proliferation activities stimulated by PHA was found.

Original languageEnglish
Pages (from-to)147-151
Number of pages5
JournalNishinihon Journal of Dermatology
Volume67
Issue number2
DOIs
Publication statusPublished - 2005

All Science Journal Classification (ASJC) codes

  • Dermatology

Fingerprint Dive into the research topics of 'Evaluation of clinical prognosis of stage II and III melanoma patients treated with hyperthermic isolated limb perfusion (HILP)'. Together they form a unique fingerprint.

Cite this